Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 11/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.41 |
| ▸ | BUB1 | O43683 | 1/20 | 0.40 |
| ▸ | PRKACG | P22612 | 1/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.40 |
| ▸ | ACSL5 | Q9ULC5 | 1/20 | 0.40 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9895791 | 0.94 | GABRA5 (0.42) | RIPK2MAPK14LCKKITKDR | |
| SCHEMBL9894508 | 0.88 | CYP2C9 (0.44) | MAPK14CYP2C9MAPK11 | |
| SCHEMBL9896773 | 0.86 | GABRA5 (0.37) | — | |
| SCHEMBL9895639 | 0.86 | MAPK14 (0.46) | RIPK2MAPK14CYP2C9MAPK11 | |
| SCHEMBL9895332 | 0.86 | SPR (0.38) | MAPK14 | |
| SCHEMBL9894897 | 0.85 | MAPT (0.43) | RIPK2MAPK14CYP2C9 | |
| SCHEMBL9895495 | 0.85 | SPR (0.37) | MAPK14 | |
| SCHEMBL9894812 | 0.84 | MAPK8 (0.40) | — | |
| SCHEMBL9895824 | 0.84 | GABRA5 (0.39) | MAPK14 | |
| SCHEMBL9895387 | 0.84 | CNR2 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649064-B1 | NOVEL TRIAZOLE COMPOUNDS III | HOFFMANN LA ROCHE (CH) | 2019-10-02 | — | — | EP | claimed |
| US-8466181-B2 | 1,2,3-triazole-imidazole compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-06-18 | — | — | US | claimed |
| US-20120149675-A1 | 1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-06-14 | — | — | US | claimed |
| EP-2649064-B1 | NOVEL TRIAZOLE COMPOUNDS III | HOFFMANN LA ROCHE (CH) | 2019-10-02 | — | — | EP | disclosed |
| EP-2649064-A1 | NOVEL TRIAZOLE COMPOUNDS III | F. Hoffmann-La Roche AG (CH) | 2013-10-16 | — | — | EP | disclosed |
| US-8466181-B2 | 1,2,3-triazole-imidazole compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466181-B2 | 1,2,3-triazole-imidazole compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-20120149675-A1 | 1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-06-14 | — | — | US | disclosed |
| WO-2012076590-A1 | NOVEL TRIAZOLE COMPOUNDS III | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-14 | — | — | WO | disclosed |
| US-20120149675-A1 | 1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-06-14 | — | — | US | disclosed |
| WO-2012076590-A1 | NOVEL TRIAZOLE COMPOUNDS III | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149675-A1 | 1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS | GABRA5, GABRA1, GABRB1 | RIPK2 2667/4885MAPK14 4554/4885LCK 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.